| Market Cap | 23.50M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -24.91M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -10.00% |
| Sales | 6.02M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -36.00% |
| Dividend | N/A | Price/Book | 0.50 | EPS next 5Y | - | 52W High Chg | -71.00% |
| Recommedations | - | Quick Ratio | 8.43 | Shares Outstanding | 1.47B | 52W Low Chg | 60.00% |
| Insider Own | 7.19% | ROA | -20.98% | Shares Float | 0.98B | Beta | 1.84 |
| Inst Own | 29.33% | ROE | -46.14% | Shares Shorted/Prior | -/- | Price | 0.02 |
| Gross Margin | -229.04% | Profit Margin | - | Avg. Volume | 184,265 | Target Price | - |
| Oper. Margin | -346.16% | Earnings Date | - | Volume | 15,000 | Change | 0.00% |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
